Return to homepagePandemic Pact

Adaptive COVID- 19 Treatment Trial (ACTT) - a randomised study of treatment of hospitalised patients with COVID-19 in Europe

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $1,586,090.4

  • Funder

    UFM Denmark

  • Principal Investigator

    Clinical Professor Jens Lundgren

  • Research Location

    Denmark

  • Lead Research Institution

    Rigshospitalet, University of Copenhagen

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The project has an international scope and is part of a global network of hospitals, which examines the possibility of treatment of hospitalised with COVID-19 where the disease has evolved into severe pneumonia. The project will examine possible treatments beginning with remdisivir, which is developed for treatment of other vira. In the trial, one will treat already hospitalised patients with known anti-viral products and the goal will be for COVID-19 patients to be treated as fast as possible and from an already safe profile of side effects.